AbbVie ImmunoGen Acquisition 2023

AbbVie's acquisition of ImmunoGen, announced November 30, 2023, accelerates the company's entry into solid tumor oncology by adding an on-market ovarian cancer drug and promising ADC pipeline. The transaction leverages ImmunoGen's folate receptor alpha-directed ADC technology and complements AbbVie's existing oncology capabilities to drive multi-billion dollar revenue potential.